Becton Dickinson and Co
BDX201.110USD
+0.220+0.11%
Market hours （ET）Quotes delayed by 15 min
57.40BMarket Cap
34.47P/E TTM
More Details of Becton Dickinson and Co Company
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Becton Dickinson and Co Info
Ticker SymbolBDX
Company nameBecton Dickinson and Co
IPO dateOct 31, 2099
CEOPolen (Thomas E)
Number of employees72000
Security typeOrdinary Share
Fiscal year-endOct 31
AddressOne Becton Drive
CityFRANKLIN LAKES
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code07417-1880
Phone12018476800
Websitehttps://www.bd.com/
Ticker SymbolBDX
IPO dateOct 31, 2099
CEOPolen (Thomas E)
Company Executives of Becton Dickinson and Co
Name
Name/Position
Position
Shareholding
Change
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Mr. Antoine C. Ezell
Mr. Antoine C. Ezell
Executive Vice President, President, North America, Chief Marketing Officer
Executive Vice President, President, North America, Chief Marketing Officer
11.97K
+28.43%
Mr. Robert Andrew (Andy) Eckert
Mr. Robert Andrew (Andy) Eckert
Independent Director
Independent Director
9.14K
+11.33%
Ms. Michelle Quinn
Ms. Michelle Quinn
Executive Vice President, General Counsel
Executive Vice President, General Counsel
6.93K
+39.80%
Mr. Gregory J. Hayes
Mr. Gregory J. Hayes
Independent Director
Independent Director
6.05K
+659.55%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard (Rick) Byrd
Mr. Richard (Rick) Byrd
Executive Vice President, President - Interventional Segment
Executive Vice President, President - Interventional Segment
761.54K
+0.94%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Independent Director
Independent Director
59.87K
+1.58%
Ms. Shana Carol Neal
Ms. Shana Carol Neal
Chief People Officer, Executive Vice President
Chief People Officer, Executive Vice President
54.82K
+16.58%
Mr. Roland Goette
Mr. Roland Goette
Executive Vice President, President - EMEA
Executive Vice President, President - EMEA
17.21K
+21.15%
Mr. Michael Feld
Mr. Michael Feld
Executive Vice President, President - Life Sciences
Executive Vice President, President - Life Sciences
16.58K
-0.45%
Ms. Catherine M. (Cathy) Burzik
Ms. Catherine M. (Cathy) Burzik
Independent Director
Independent Director
14.81K
+6.70%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
Other
1.88B
34.09%
By RegionUSD
Name
Revenue
Proportion
United States
3.18B
57.72%
International
2.33B
42.26%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Medication Delivery Solutions
1.13B
20.55%
Medication Management Solutions
888.00M
16.12%
Pharmaceutical Systems
629.00M
11.42%
Peripheral Intervention
512.00M
9.29%
Specimen Management
470.00M
8.53%
Other
1.88B
34.09%
Shareholding Stats
Updated: Sat, Nov 15
Updated: Sat, Nov 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
Other
69.45%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
11.32%
T. Rowe Price Investment Management, Inc.
5.69%
BlackRock Institutional Trust Company, N.A.
5.17%
State Street Investment Management (US)
4.86%
First Eagle Investment Management, L.L.C.
3.50%
Other
69.45%
Shareholder Types
Shareholders
Proportion
Investment Advisor
48.65%
Investment Advisor/Hedge Fund
35.74%
Research Firm
2.91%
Pension Fund
2.39%
Bank and Trust
1.46%
Hedge Fund
1.42%
Sovereign Wealth Fund
1.36%
Individual Investor
0.60%
Insurance Company
0.32%
Other
5.13%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
2786
268.89M
98.17%
+69.96K
2025Q3
2887
268.83M
99.00%
+3.34M
2025Q2
2905
265.92M
96.81%
+120.40K
2025Q1
2872
266.25M
96.81%
-11.23M
2024Q4
2862
265.61M
95.72%
+1.13M
2024Q3
2775
265.14M
93.34%
+4.39M
2024Q2
2770
259.79M
92.17%
+1.30M
2024Q1
2779
258.85M
91.59%
-5.84M
2023Q4
2763
257.96M
92.19%
-5.24M
2023Q3
2735
263.83M
91.15%
+1.97M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
32.17M
11.22%
+4.30M
+15.41%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
16.18M
5.64%
+3.60M
+28.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
15.15M
5.29%
+360.45K
+2.44%
Jun 30, 2025
State Street Investment Management (US)
13.41M
4.68%
-579.46K
-4.14%
Jun 30, 2025
First Eagle Investment Management, L.L.C.
8.79M
3.07%
+3.27M
+59.18%
Jun 30, 2025
MFS Investment Management
7.69M
2.68%
+1.58M
+25.78%
Jun 30, 2025
Geode Capital Management, L.L.C.
6.72M
2.35%
+244.20K
+3.77%
Jun 30, 2025
ClearBridge Investments, LLC
3.80M
1.33%
+321.67K
+9.24%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares U.S. Medical Devices ETF
4.25%
FPA Global Equity ETF
3.12%
Cullen Enhanced Equity Income ETF
3.1%
American Century Focused Large Cap Value ETF
3.04%
iShares Large Cap Value Active ETF
2.72%
First Eagle Global Equity ETF
2.66%
Franklin ClearBridge Enhanced Income ETF
2.66%
T Rowe Price Capital Appreciation Equity ETF
2.65%
Brandes US Value ETF
2.26%
First Trust Indxx Medical Devices ETF
1.92%
View more
iShares U.S. Medical Devices ETF
Proportion4.25%
FPA Global Equity ETF
Proportion3.12%
Cullen Enhanced Equity Income ETF
Proportion3.1%
American Century Focused Large Cap Value ETF
Proportion3.04%
iShares Large Cap Value Active ETF
Proportion2.72%
First Eagle Global Equity ETF
Proportion2.66%
Franklin ClearBridge Enhanced Income ETF
Proportion2.66%
T Rowe Price Capital Appreciation Equity ETF
Proportion2.65%
Brandes US Value ETF
Proportion2.26%
First Trust Indxx Medical Devices ETF
Proportion1.92%
Dividend
A total of
5.54B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 06, 2025
BDX.NB Final Cash Dividend of gross USD 1.05 paid on Dec 31, 2025 going ex on Dec 08, 2025
Dec 08, 2025
Dec 31, 2025
Dec 08, 2025
Jul 22, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Sep 30, 2025 going ex on Sep 08, 2025
Sep 08, 2025
Sep 30, 2025
Sep 08, 2025
Apr 29, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Jun 30, 2025 going ex on Jun 09, 2025
Jun 09, 2025
Jun 30, 2025
Jun 09, 2025
Jan 28, 2025
BDX.NB Interim Cash Dividend of gross USD 1.04 paid on Mar 31, 2025 going ex on Mar 10, 2025
Mar 10, 2025
Mar 31, 2025
Mar 10, 2025
Nov 07, 2024
BDX.NB Final Cash Dividend of gross USD 1.04 paid on Dec 31, 2024 going ex on Dec 09, 2024
Dec 09, 2024
Dec 31, 2024
Dec 09, 2024
Jul 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Sep 30, 2024 going ex on Sep 09, 2024
Sep 09, 2024
Sep 30, 2024
Sep 09, 2024
Apr 30, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Jun 28, 2024 going ex on Jun 10, 2024
Jun 10, 2024
Jun 28, 2024
Jun 10, 2024
Jan 23, 2024
BDX.NB Interim Cash Dividend of gross USD 0.95 paid on Mar 29, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Mar 29, 2024
Mar 07, 2024
Nov 09, 2023
BDX.NB Final Cash Dividend of gross USD 0.95 paid on Dec 29, 2023 going ex on Dec 07, 2023
Dec 08, 2023
Dec 29, 2023
Dec 07, 2023
Jul 25, 2023
BDX.NB Interim Cash Dividend of gross USD 0.91 paid on Sep 29, 2023 going ex on Sep 07, 2023
Sep 08, 2023
Sep 29, 2023
Sep 07, 2023
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Becton Dickinson and Co?
The top five shareholders of Becton Dickinson and Co are:
The Vanguard Group, Inc. holds 32.17M shares, accounting for 11.22% of the total shares.
T. Rowe Price Investment Management, Inc. holds 16.18M shares, accounting for 5.64% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 15.15M shares, accounting for 5.29% of the total shares.
State Street Investment Management (US) holds 13.41M shares, accounting for 4.68% of the total shares.
First Eagle Investment Management, L.L.C. holds 8.79M shares, accounting for 3.07% of the total shares.
The Vanguard Group, Inc. holds 32.17M shares, accounting for 11.22% of the total shares.
T. Rowe Price Investment Management, Inc. holds 16.18M shares, accounting for 5.64% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 15.15M shares, accounting for 5.29% of the total shares.
State Street Investment Management (US) holds 13.41M shares, accounting for 4.68% of the total shares.
First Eagle Investment Management, L.L.C. holds 8.79M shares, accounting for 3.07% of the total shares.
What are the top three shareholder types of Becton Dickinson and Co?
The top three shareholder types of Becton Dickinson and Co are:
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
The Vanguard Group, Inc.
T. Rowe Price Investment Management, Inc.
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Becton Dickinson and Co (BDX)?
As of 2025Q4, 2786 institutions hold shares of Becton Dickinson and Co, with a combined market value of approximately 268.89M, accounting for 98.17% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.83%.
What is the biggest source of revenue for Becton Dickinson and Co?
In FY2025Q3, the Medication Delivery Solutions business generated the highest revenue for Becton Dickinson and Co, amounting to 1.13B and accounting for 20.55% of total revenue.
